Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2007 May 7;96(9):1462-8.
doi: 10.1038/sj.bjc.6603717. Epub 2007 Apr 3.

Comorbidity and survival of Danish breast cancer patients from 1995 to 2005

D P Cronin-Fenton  1 , M Nørgaard, J Jacobsen, J P Garne, M Ewertz, T L Lash, H T Sørensen
Affiliations
Multicenter Study

Comorbidity and survival of Danish breast cancer patients from 1995 to 2005

D P Cronin-Fenton et al. Br J Cancer. .

Abstract

Comorbid diseases can affect breast cancer prognosis. We conducted a population-based study of Danish women diagnosed with a first primary breast cancer from 1995 to 2005 (n=9300), using hospital discharge registry data to quantify comorbidities by Charlson score. We examined the influence of comorbidities on survival, and quantified their impact on relative mortality rates. The prevalence of patients with a Charlson score='0' fell from 86 to 81%, with an increase in those with Charlson score='1-2' from 13 to 16%, and score='3+' from 1 to 2%. One- and five-year survival for patients with Charlson score='0' and '1-2' was better for those diagnosed in 1998-2000 than in 1995-1997. Overall, patients diagnosed in 2001-2004 (mortality ratio (MR)=0.80, 95% CI=0.68-0.95) and 1998-2000 (MR=0.92, 95% CI=0.78-1.09) had lower 1-year age-adjusted mortality compared to those diagnosed in 1995-1997 (reference period). Patients with Charlson scores '1-2' and '3+' had higher age-adjusted 1-year mortality than those with a Charlson score='0' in each time period (2001-2004: MR('1-2')=1.76, 95% CI=1.35-2.30, and MR('3+')=3.78, 95% CI=2.51-5.68; and 1998-2000: MR('1-2')=1.60, 95% CI=1.36-1.88 and MR('3+')=2.34, 95% CI=1.65-3.33). Similar findings were observed for 5-year age-adjusted mortality. Additional analyses, adjusted for stage, indicated that confounding by stage could not explain these findings. Despite continued improvements in breast cancer survival, we found a trend of poorer survival among breast cancer patients with severe comorbidities even after adjusting for age and stage. Such poorer survival is an important public health concern and can be expected to worsen as the population ages.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier survival curves for patients with breast cancer in Denmark for three time periods for (A) Charlson score=0, (B) Charlson score=1–2, and (C) Charlson score=3+.
See this image and copyright information in PMC

References

    1. Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, Swanson CA, Brinton LA, Eley JW, Coates RJ (2006) General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev 15: 1871–1877 - PubMed
    1. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA (2005) Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol 34: 405–412 - PubMed
    1. Andersen IB, Bonnevie O, Jorgensen T, Sorensen TI (1999) Peptic ulcer in Denmark, 1981–1993. Analysis of data from national patient registries. Ugeskr Laeg 161: 1589–1594 - PubMed
    1. Bastarrachea J, Hortobagyi GN, Smith TL, Kau SW, Buzdar AU (1994) Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med 120: 18–25 - PubMed
    1. Bendixen H, Holst C, Sorensen TI, Raben A, Bartels EM, Astrup A (2004) Major increase in prevalence of overweight and obesity between 1987 and 2001 among Danish adults. Obes Res 12: 1464–1472 - PubMed

Publication types